Amniotic Fluid Stem Cell EVs Modulate VEGF in Kidney Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The mechanisms behind the renoprotective effects of amniotic fluid stem cells (AFSC) in delaying renal fibrosis and improving kidney function in Alport Syndrome are not fully understood, particularly regarding their modulation of vascular endothelial growth factor (VEGF) signaling in glomerular endothelial cells.

Innovation Solution

Extracellular vesicles (EVs) secreted by AFSC, expressing VEGFR1 and VEGFR2, trap excess VEGF to modulate signaling pathways, thereby mitigating endothelial damage and promoting renal protection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If amniotic fluid stem cells (AFSC) are injected to treat Alport Syndrome, then kidney function is improved and renal fibrosis is delayed, but the mechanism of action is not fully understood and requires further investigation

Engineering Contradiction:

Improvekidney functionVSAvoidmechanism understanding

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent extracts and isolates extracellular vesicles (EVs) from amniotic fluid stem cells (AFSC) to study their specific renoprotective mechanisms. By separating EVs from whole cells, the research can focus on the molecular components and signaling pathways carried by these vesicles, thereby understanding how AFSC exert their protective effects without the complexity of living cell behavior

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent identifies extracellular vesicles as intermediary carriers that transfer protective signals from AFSC to damaged kidney tissue. These EVs contain microRNAs and other bioactive molecules that mediate the therapeutic effect, serving as a bridge between the stem cells and the target tissue, thus elucidating the mechanism of action

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If VEGF signaling is elevated in glomerular endothelial cells, then disease progression occurs, but excessive VEGF causes endothelial cell damage

Engineering Contradiction:

Improveglomerular functionVSAvoidendothelial cell damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of excessive VEGF signaling into a beneficial therapeutic mechanism by using AFSC-derived EVs to deliver controlled VEGF modulation. The EVs carry microRNAs that regulate VEGF expression, transforming the pathogenic overactivation into a controlled, protective signaling pathway that prevents endothelial damage while maintaining necessary vascular function

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the parameter of VEGF signaling from excessive/unchecked to regulated/controlled through the action of AFSC-derived EVs. The EVs modulate VEGF levels and signaling intensity, transforming the pathological high-state into a physiological optimal-state, thereby protecting endothelial cells while preserving glomerular function

Inventive Principle:

Principle #35Parameter changes

3Reliability

If extracellular vesicles from AFSC are used to target VEGF signaling, then specific glomerular protection is achieved, but the complexity of isolating and characterizing EVs increases

Engineering Contradiction:

Improveglomerular protectionVSAvoidEV isolation process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the complex AFSC system into discrete extracellular vesicles that can be isolated and characterized separately. By focusing on EVs rather than whole cells, the research divides the therapeutic system into manageable components, simplifying the isolation and mechanistic study processes while maintaining therapeutic efficacy

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses extracellular vesicles as simplified copies or proxies of the full AFSC system. EVs contain the essential therapeutic information (microRNAs, proteins) from AFSC but lack the complexity of living cells, making them easier to isolate, store, and study while reproducing the key renoprotective effects

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

AFSC-derived EVs effectively target and restore VEGF signaling in glomerular endothelial cells, delaying renal fibrosis and enhancing kidney function in Alport Syndrome.

Implementation Method 1

Extracellular vesicles were able to modulate VEGF in glomerular endothelial cells by effectively trapping the excess VEGF through VEGFR1-binding preventing cellular damage

Methodology Applied

Scientific EffectVEGF trapping: Absorption (physical)

Data Source

PatentEP3538069B1Extracellular vesicles from stem cells for use in a treatment of chronic kidney diseases

Publication Date: 2025.09.03 BUSSOLATI BENEDETTA

Figure 1A
Figure 1B~1C
Figure 1D~1E

AI summary

Compositions and methods to treat or prevent disease or injury comprising administering an effective amount of extracellular vesicles (EVs) isolated from stem cells to a subject in need thereof.